Want to see TW:6541 full AI Analyst Report?
Tanvex Biopharma (6541) Stock Statistics & Valuation Metrics
Total Valuation
Tanvex Biopharma has a market cap or net worth of TWD 7.39B. The enterprise value is TWD 12.13B.
- Market Cap
- TWD 7.39B
- Enterprise Value
- TWD 12.13B
Share Statistics
Tanvex Biopharma has 265,224,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 265,224,370
- Owned by Insiders
- ―
- Owned by Institutions
- 0.06%
Financial Efficiency
Tanvex Biopharma’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -18.79%.
- Return on Equity (ROE)
- -0.26
- Return on Assets (ROA)
- -0.19
- Return on Invested Capital (ROIC)
- -18.79%
- Return on Capital Employed (ROCE)
- -0.19
- Revenue Per Employee
- 1.86M
- Profits Per Employee
- -6.98M
- Employee Count
- 215
- Asset Turnover
- 0.05
- Inventory Turnover
- 2.02
Valuation Ratios
The current PE Ratio of Tanvex Biopharma is -5.24. Tanvex Biopharma’s PEG ratio is -0.21.
- PE Ratio
- -5.24
- PS Ratio
- 11.81
- PB Ratio
- 1.56
- Price to FCF
- -4.45
- Price to Operating Cash Flow
- -8.31
- PEG Ratio
- -0.21
Income Statement
In the last 12 months, Tanvex Biopharma had revenue of 400.97M and earned -1.50B in profits. Earnings per share was -6.13.
- Revenue
- 400.97M
- Gross Profit
- -440.71M
- Operating Income
- -1.39B
- Pretax Income
- -1.50B
- Net Income
- -1.50B
- EBITDA
- -1.02B
- Earnings Per Share (EPS)
- -6.13
Cash Flow
In the last 12 months, operating cash flow was -934.97M and capital expenditures -811.47M, giving a free cash flow of -1.75B billion.
- Operating Cash Flow
- -934.97M
- Free Cash Flow
- -1.75B
- Free Cash Flow per Share
- -6.59
Dividends & Yields
Tanvex Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.65%
- Earnings Yield
- -18.99%
Stock Price Statistics
- Beta
- 0.38
- 52-Week Price Change
- -51.05%
- 50-Day Moving Average
- 30.80
- 200-Day Moving Average
- 38.73
- Relative Strength Index (RSI)
- 38.55
- Average Volume (3m)
- 432.00K
Important Dates
Tanvex Biopharma upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Tanvex Biopharma as a current ratio of 1.87, with Debt / Equity ratio of 27.72%
- Current Ratio
- 1.87
- Quick Ratio
- 1.35
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.68
- Interest Coverage Ratio
- -29.39
Taxes
In the past 12 months, Tanvex Biopharma has paid -3.05M in taxes.
- Income Tax
- -3.05M
- Effective Tax Rate
- 0.00
Enterprise Valuation
Tanvex Biopharma EV to EBITDA ratio is -9.00, with an EV/FCF ratio of -5.27.
- EV to Sales
- 13.99
- EV to EBITDA
- -9.00
- EV to Free Cash Flow
- -5.27
- EV to Operating Cash Flow
- -9.84
Balance Sheet
Tanvex Biopharma has TWD 592.56M in cash and marketable securities with TWD 2.08B in debt, giving a net cash position of -TWD 1.49B billion.
- Cash & Marketable Securities
- TWD 592.56M
- Total Debt
- TWD 2.08B
- Net Cash
- -TWD 1.49B
- Net Cash Per Share
- -TWD 5.62
- Tangible Book Value Per Share
- TWD 5.88
Margins
Gross margin is -149.75%, with operating margin of -217.02%, and net profit margin of -222.84%.
- Gross Margin
- -149.75%
- Operating Margin
- -217.02%
- Pretax Margin
- -222.83%
- Net Profit Margin
- -222.84%
- EBITDA Margin
- -155.52%
- EBIT Margin
- -213.36%
Analyst Forecast
The average price target for Tanvex Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 492.43%
- EPS Growth Forecast
- 21.57%
Scores
- Smart Score
- ―
- AI Score
- 43
